Shares of TG Therapeutics Inc. (NASDAQ:TGTX) traded down 3.3% on Thursday . The company traded as low as $5.85 and last traded at $5.87, with a volume of 148,806 shares changing hands. The stock had previously closed at $6.07.

A number of analysts have recently weighed in on the company. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. Brean Capital reissued a “buy” rating on shares of TG Therapeutics in a report on Tuesday, May 31st. Roth Capital reissued a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Thursday, June 9th. Finally, SunTrust Banks Inc. initiated coverage on TG Therapeutics in a report on Friday, May 27th. They set a “buy” rating and a $18.00 price target for the company. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $22.75.

The stock’s market capitalization is $325.54 million. The stock has a 50-day moving average price of $6.11 and a 200 day moving average price of $7.92.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. Equities analysts forecast that TG Therapeutics Inc. will post ($1.15) earnings per share for the current year.

A hedge fund recently raised its stake in TG Therapeutics stock. New York State Common Retirement Fund boosted its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 as of its most recent SEC filing.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.